OmniAb (NASDAQ:OABIW – Get Free Report) is expected to issue its results before the market opens on Wednesday, March 4th. Analysts expect the company to announce earnings of ($0.0880) per share and revenue of $9.0030 million for the quarter.
OmniAb Stock Performance
Shares of OABIW stock opened at $0.09 on Wednesday. The stock’s fifty day moving average price is $0.11 and its 200 day moving average price is $0.14. OmniAb has a 1-year low of $0.08 and a 1-year high of $0.63.
OmniAb Company Profile
OmniAb, Inc is a clinical‐stage biotechnology company specializing in the discovery and optimization of therapeutic antibodies. The company leverages a broad suite of proprietary platform technologies designed to accelerate antibody generation, characterization, and engineering. By integrating advanced immunization methods with high‐throughput screening and bioinformatics, OmniAb aims to streamline the development of next‐generation biologics across a range of disease areas.
At the core of OmniAb’s offering are its transgenic animal platforms, which have been engineered to produce fully human antibodies, and its complementary in vitro display and single‐cell screening capabilities.
Recommended Stories
- Five stocks we like better than OmniAb
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- Buy this Gold Stock Before May 2026
- This makes me furious
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.
